Isabelle Vigon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Isabelle Vigon has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Amélie Valérie Guitart
Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom
1 shared publication - Angela Ianniciello
Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK
1 shared publication Antonia Boudet
Aix Marseille University, INSERM, CNRS, Institut Paoli-Calmettes, CRCM-Cancer Research Center of Marseille, Marseille, France
1 shared publicationArmelle Goubard
Aix Marseille University, INSERM, CNRS, Institut Paoli-Calmettes, CRCM-Cancer Research Center of Marseille, Marseille, France
1 shared publication- Arnaud Villacreces
Cellules Souches Hématopoïétiques Normales et Leucémiques, INSERM U1312 BRIC, Université de Bordeaux, Bat TP 4e étage, 146 rue Léo Saignat, 33076 Bordeaux, France
1 shared publication - Claire Drullion
Bordeaux University, CNRS , ImmunoConcept, UMR 5164, 33000 Bordeaux , France
1 shared publication
Latest Publications
- Open Access
- 29 August 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (10) , 2632-2660
Dual targeting of CDK6 and LSD1 is synergistic and overcomes differentiation blockade in AML
The heterogeneity of leukemic cells is the main cause of resistance to therapy in acute myeloid leukemia (AML). Consequently, innovative therapeutic approaches are critical to target a wide spectrum of leukemic clones, regardless of their genetic and non-genetic complexity. In this report, we leverage the vulnerability of AML cells to CDK6 to identify a combination therapy capable of targeting common biological processes shared by all leukemic cells, while sparing non-transformed cells. We demonstrate that the combined inhibition of CDK6 and LSD1 restores myeloid differentiation and depletes the leukemic progenitor compartment in AML samples. Mechanistically, this combination induces major changes in chromatin accessibility, leading to the transcription of differentiation genes and diminished LSC signatures. Remarkably, the combination is synergistic, induces durable changes in the cells, and is effective in PDX mouse models. While many AML samples exhibit only modest responses to LSD1 inhibition, co-targeting CDK6 restores the expected transcription response associated with LSD1 inhibition. Given the availability of clinical-grade CDK6 and LSD1 inhibitors, this combination holds significant potential for implementation in clinical settings through drug repositioning.
- 29 August 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (10) , 2632-2660
Open AccessDual targeting of CDK6 and LSD1 is synergistic and overcomes differentiation blockade in AML
The heterogeneity of leukemic cells is the main cause of resistance to therapy in acute myeloid leukemia (AML). Consequently, innovative therapeutic approaches are critical to target a wide spectrum of leukemic clones, regardless of their genetic and non-genetic complexity. In this report, we leverage the vulnerability of AML cells to CDK6 to identify a combination therapy capable of targeting common biological processes shared by all leukemic cells, while sparing non-transformed cells. We demonstrate that the combined inhibition of CDK6 and LSD1 restores myeloid differentiation and depletes the leukemic progenitor compartment in AML samples. Mechanistically, this combination induces major changes in chromatin accessibility, leading to the transcription of differentiation genes and diminished LSC signatures. Remarkably, the combination is synergistic, induces durable changes in the cells, and is effective in PDX mouse models. While many AML samples exhibit only modest responses to LSD1 inhibition, co-targeting CDK6 restores the expected transcription response associated with LSD1 inhibition. Given the availability of clinical-grade CDK6 and LSD1 inhibitors, this combination holds significant potential for implementation in clinical settings through drug repositioning.
- Open Access
- 30 June 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (57) , 96984-96992
Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence
Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence
- 30 June 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (57) , 96984-96992
Open AccessChronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence
Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence
- Open Access
- 15 November 2000
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 352 (1) , 49-59
Polydom: a secreted protein with pentraxin, complement control protein, epidermal growth factor and von Willebrand factor A domains
To identify extracellular proteins with epidermal growth factor (EGF) domains that are potentially involved in the control of haemopoiesis, we performed degenerate reverse-transcriptase-mediated PCR on the murine bone-marrow stromal cell line MS-5 and isolated a new partial cDNA encoding EGF-like domains related to those in the Notch proteins. Cloning and sequencing of the full-length cDNA showed that it encoded a new extracellular multi-domain protein that we named polydom. This 387kDa mosaic protein contained a signal peptide followed by a new association of eight different protein domains, including a pentraxin domain and a von Willebrand factor type A domain, ten EGF domains, and 34 complement control protein modules. The human polydom mRNA is strongly expressed in placenta, its expression in the other tissues being weak or undetectable. The particular multidomain structure of the encoded protein suggests an important biological role in cellular adhesion and/or in the immune system.
- 15 November 2000
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 352 (1) , 49-59
Open AccessPolydom: a secreted protein with pentraxin, complement control protein, epidermal growth factor and von Willebrand factor A domains
To identify extracellular proteins with epidermal growth factor (EGF) domains that are potentially involved in the control of haemopoiesis, we performed degenerate reverse-transcriptase-mediated PCR on the murine bone-marrow stromal cell line MS-5 and isolated a new partial cDNA encoding EGF-like domains related to those in the Notch proteins. Cloning and sequencing of the full-length cDNA showed that it encoded a new extracellular multi-domain protein that we named polydom. This 387kDa mosaic protein contained a signal peptide followed by a new association of eight different protein domains, including a pentraxin domain and a von Willebrand factor type A domain, ten EGF domains, and 34 complement control protein modules. The human polydom mRNA is strongly expressed in placenta, its expression in the other tissues being weak or undetectable. The particular multidomain structure of the encoded protein suggests an important biological role in cellular adhesion and/or in the immune system.
- Open Access
- 1 August 1993
- Published by American Society of Hematology in Blood
- Vol. 82 (3) , 877-883
Expression of the c-mpl proto-oncogene in human hematologic malignancies
Similar to two other hematopoietic growth factor receptors, the c-fms (macrophage colony-stimulating factor receptor) and the c-kit genes, c- mpl has been discovered through the study of oncogenic retroviruses. Unlike c-fms and c-kit, which both belong to a subgroup of tyrosine kinase receptors, the c-mpl proto-oncogene encodes a new member of the cytokine receptor superfamily. We have studied the expression of c-mpl in a series of 105 patients with hematologic malignancies using Northern blot analysis. The levels of c-mpl transcripts in lymphoid malignancies and in chronic myeloproliferative disorders were not significantly different from those found in normal bone marrow cells, in which c-mpl was barely detectable. In contrast, c-mpl expression was increased in 26 of 51 patients with acute myeloblastic leukemia (AML) and in 5 of 16 patients with myelodysplastic syndromes. Amplification of the c-mpl gene was detected in genomic DNA of one M4 AML patient. There was no significant correlation between c-mpl expression and the French-American-British classification of AML. Patients with high c-mpl expression appeared to belong to a subgroup of AML with a low rate of complete remission and a poor prognosis, including secondary leukemia and AML with unfavorable cytogenetic abnormalities.
- 1 August 1993
- Published by American Society of Hematology in Blood
- Vol. 82 (3) , 877-883
Open AccessExpression of the c-mpl proto-oncogene in human hematologic malignancies
Similar to two other hematopoietic growth factor receptors, the c-fms (macrophage colony-stimulating factor receptor) and the c-kit genes, c- mpl has been discovered through the study of oncogenic retroviruses. Unlike c-fms and c-kit, which both belong to a subgroup of tyrosine kinase receptors, the c-mpl proto-oncogene encodes a new member of the cytokine receptor superfamily. We have studied the expression of c-mpl in a series of 105 patients with hematologic malignancies using Northern blot analysis. The levels of c-mpl transcripts in lymphoid malignancies and in chronic myeloproliferative disorders were not significantly different from those found in normal bone marrow cells, in which c-mpl was barely detectable. In contrast, c-mpl expression was increased in 26 of 51 patients with acute myeloblastic leukemia (AML) and in 5 of 16 patients with myelodysplastic syndromes. Amplification of the c-mpl gene was detected in genomic DNA of one M4 AML patient. There was no significant correlation between c-mpl expression and the French-American-British classification of AML. Patients with high c-mpl expression appeared to belong to a subgroup of AML with a low rate of complete remission and a poor prognosis, including secondary leukemia and AML with unfavorable cytogenetic abnormalities.